Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer by Bei Wang (116772)

“…</p> <p><b>Results:</b> Decreased inflammation was found to be associated with increased CD3⁺ and CD8⁺ T-cell infiltration and a better prognosis. …”

Image 1_Augmentation of bone formation by sympathectomy in rats as evaluated by [99mTc]Tc-MDP.png by Zili Cai (15238729)

“…SCGx rats exhibited significantly higher [^99mTc]Tc-MDP uptake and increased BMD, BV/TV, and BV in peri-fracture regions at all time points (p < 0.0001). …”

Table 2_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Table 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Image 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.tiff by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Table 3_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Table 4_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.xlsx by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Transcriptomic analysis of AMPK and HZL-1 mutants reveals widespread gene expression differences predominantly in the germ line. by Sabih Rashid (5618807)

“…<p><b>A)</b> and <b>B)</b> Bubble plots depicting most enriched GO terms in <i><i>daf-2</i></i>, <i><i>daf-2, aak(0)</i>,</i> and <i><i>aak(0); hzl-1</i></i> transcriptomes, ranked by significance based on p-value. …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The survival benefits were consistent across all subgroups and increases with longer follow-up. …”